ARS Pharma rises on expanded US approval for allergic reaction nasal spray

ARS Pharmaceuticals

06/03/2025 13:37

** Shares of drug developer ARS Pharmaceuticals SPRY.O rise 2.6% to $11.15 premarket

** Co said late on Wednesday the U.S. FDA approved the expanded use of nasal spray for severe allergic reactions in patients who weigh between 15 kg and 30 kg

** The spray, sold under the brand name neffy, will be dosed at 1 mg for the new patient population

** Neffy is designed to be given at the first sign of a severe allergic reaction, and has been previously approved for people above 30 kg at dose of 2 mg

** SPRY has risen 21.5% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))